ClinicalTrials.Veeva

Menu
N

Northridge Clinical Trials | Northridge, CA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Amlitelimab
Rocatinlimab
Ixekizumab
Tirzepatide
TAK-279
Lorundrostat
LY4005130
Ritlecitinib
Tulisokibart
PF-07275315

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

18 of 24 total trials

A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.

The purpose of this study is to learn about the safety and effects of the study medicine (called Ritlecitinib) for the possible treatment of hidraden...

Enrolling
Hidradenitis Suppurativa
Drug: Ritlecitinib
Drug: Placebo

TRANSFORM is a prospective, randomized, open blinded endpoint (PROBE), event-driven, pragmatic trial in patients who are at increased risk for athero...

Enrolling
Diabetes Mellitus, Type 2
Metabolic Syndrome
Device: The Cleerly CAD Staging System
Status recently updated

The purpose of this study is to evaluate how well LY4005130 is tolerated and what side effects may occur in participants with non-segmental vitiligo...

Not yet enrolling
Enrolling
Vitiligo
Non-Segmental Vitiligo (NSV)
Drug: Placebo
Drug: LY4005130
Status recently updated

The purpose of this study is to evaluate how well LY4005130 works in participants with severe alopecia areata (hair loss) when compared with placebo,...

Not yet enrolling
Enrolling
Alopecia Areata
Drug: LY4005130
Drug: Placebo

The main aim of this study is to check the side effects of TAK-279 and how well it is tolerated in participants with moderate-to-severe plaque psoria...

Active, not recruiting
Plaque Psoriasis
Drug: TAK-279

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Active, not recruiting
Atopic Dermatitis
Other: Placebo
Drug: Rocatinlimab

The purpose of this study is to evaluate the efficacy, safety, and drug levels of Deucravacitinib (BMS-986165) in adolescent participants with modera...

Enrolling
Plaque Psoriasis
Drug: Deucravacitinib
Other: Placebo

This is a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 3 study for treatment of participants aged 12 yea...

Active, not recruiting
Dermatitis Atopic
Drug: Placebo
Drug: Amlitelimab

The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participan...

Enrolling
Psoriasis
Overweight or Obesity
Drug: Tirzepatide

The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic der...

Enrolling
Atopic Dermatitis
Drug: PF-07275315
Other: Placebo

The main purpose of this study is to demonstrate that when participants with moderate to severe plaque psoriasis and obesity or overweight in the pre...

Active, not recruiting
Psoriasis
Obesity
Drug: Tirzepatide
Drug: Ixekizumab

This is an open-label, Phase 2/Phase 3, long-term extension study for treatment of participants of previous amlitelimab clinical trials in moderate t...

Invitation-only
Dermatitis Atopic
Drug: Topical calcineurin inhibitors
Drug: Topical corticosteroids

The objective of the ESK-001-018 long term extension is to evaluate the safety and efficacy of ESK-001 over time. The scientific questions it aims to...

Active, not recruiting
Psoriasis
Severe Psoriasis
Drug: Open-Label Envudeucitinib
Drug: Blinded Envudeucitinib

This study is to evaluate the long-term safety, efficacy and tolerability of lorundrostat (an aldosterone synthase inhibitor) in subjects with hypert...

Active, not recruiting
Hypertension
Drug: lorundrostat
Drug: Placebo

This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe chronic spontaneous urticaria (CSU).

Active, not recruiting
Chronic Spontaneous Urticaria
Drug: EVO756
Drug: Placebo control

The purpose of the trial is to evaluate the safety, efficacy and immunogenicity of up to 3 intramuscular injections of the Acne mRNA vaccine candidat...

Enrolling
Acne
Other: Placebo
Biological: Acne mRNA vaccine

This is a phase 2b randomized, double-blind, placebo-controlled study of the safety and efficacy of tulisokibart in participants with moderate to sev...

Active, not recruiting
Hidradenitis Suppurativa
Drug: Placebo
Drug: Tulisokibart

The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 16 weeks (Period...

Enrolling
Hidradenitis Suppurativa (HS)
Biological: Tibulizumab Dose B
Other: Placebo

Trial sponsors

Lilly logo
Sanofi logo
Amgen logo
M
Pfizer logo
Takeda logo
A
Bristol-Myers Squibb (BMS) logo
C
E

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems